Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Priming of T cell responses 2
Published on November 30, 2017 19 min
Other Talks in the Series: Immunotherapy of Cancer
Immunotherapy in neuroendocrine tumors 2 - role of immunotherapy
- Dr. Nitya Raj
- Memorial Sloan Kettering Cancer Center, USA
Immune checkpoint blockade in CNS tumors
- Dr. Md. David A. Reardon
- Center for Neuro-Oncology Dana-Farber Cancer Institute, USA
Hi, this is Victor Appay speaking from The National Institute of Health and Medical Research in France. In the second part of my talk, I will concentrate more on the relationship of T cell priming in the context of tumour micro-environment, and its application in the context of cancer immunotherapy and aging.
Now in this fourth part, I will discuss about T cell priming in the context of the tumour micro-environment.
It has been shown that upon injection in mice, naive cells can infiltrate directly tumours, and this has been associated with an improved survival of the mice bearing the tumours.
Interestingly, increasing evidence support that tumours can support the infiltration, activation, and effector differentiation of naive CD8 T cells. Indeed, the adoptive transfer of naive tumour-specific CD8 T cells, into tumour-bearing mice, has been associated with the accumulation of activated CD8 T cells in the tumours, the acquisition of effector function, and the presentation of antigen to these cells by cross-presenting antigen presenting cells. Also, the recruitment of naive T cell within tumours has been shown to be favoured by the presence of high endothelial venules or HEVs. HEVs have been identified in a range of human tumours, and usually their presence has been associated with the observation of CD8 T effector cells, B cells, Th1 cells within the tumours, and organised into so-called tertiary lymphoid structures or TLS.